Fluoride therapy for the vertebral crush fracture syndrome

A status report

R. P. Heaney, D. J. Baylink, C. C. Johnston, L. J. Melton, P. J. Meunier, T. M. Murray, C. N. De Deuxchaisnes

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

FLUORIDE HAS BEEN PROPOSED as a therapy for the vertebral crush fracture syndrome for many years; such proposals have been based largely on the well-characterized syndrome of fluoride intoxication (fluorosis), which is marked by increased skeletal mass and sometimes exuberant bony overgrowths. For various reasons, including the inability to develop a patentable product, the clinical studies necessary to follow this lead and establish efficacy and safety have proceeded slowly. Nevertheless, much information on fluoride use in the treatment of the vertebral crush fracture syndrome has been amassed, and during the past 9 years fluoride therapy has been approved for this use in Austria, Belgium, France, Germany, Luxembourg, The Netherlands, Norway, and Switzerland. This report represents points of concurrence regarding the efficacy and safety of fluoride therapy and considerations relevant to patient management that were developed among conferees at the International Workshop on Fluoride and Bone, Niagara-on-the-Lake, Ontario, Canada, October 12-15, 1988. Involved in this conference were most of the investigators, worldwide, whose work was the basis for the approval of fluoride use in the European nations just listed. Hence, although the conference concentrated mainly on data not previously available, the conferees were also familiar with the evidence on which the earlier approvals had been made. In evaluating the available studies, especially regarding efficacy, the panel convened to articulate a consensus statement that paid particular attention to the criteria respecting quality of evidence developed by the Canadian Task Force on the Periodic Health Examination, 1988, and the United States Preventive Services Task Force, 1988.

Original languageEnglish
JournalJournal of Bone and Mineral Research
Volume5
Issue numberSUPPL. 1
StatePublished - 1990

Fingerprint

Crush Syndrome
Fluorides
Advisory Committees
Therapeutics
Luxembourg
Safety
Austria
Belgium
Ontario
Norway
Lakes
Switzerland
Netherlands
France
Canada
Germany
Crush Injuries
Research Personnel
Education
Bone and Bones

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Heaney, R. P., Baylink, D. J., Johnston, C. C., Melton, L. J., Meunier, P. J., Murray, T. M., & De Deuxchaisnes, C. N. (1990). Fluoride therapy for the vertebral crush fracture syndrome: A status report. Journal of Bone and Mineral Research, 5(SUPPL. 1).

Fluoride therapy for the vertebral crush fracture syndrome : A status report. / Heaney, R. P.; Baylink, D. J.; Johnston, C. C.; Melton, L. J.; Meunier, P. J.; Murray, T. M.; De Deuxchaisnes, C. N.

In: Journal of Bone and Mineral Research, Vol. 5, No. SUPPL. 1, 1990.

Research output: Contribution to journalArticle

Heaney, RP, Baylink, DJ, Johnston, CC, Melton, LJ, Meunier, PJ, Murray, TM & De Deuxchaisnes, CN 1990, 'Fluoride therapy for the vertebral crush fracture syndrome: A status report', Journal of Bone and Mineral Research, vol. 5, no. SUPPL. 1.
Heaney RP, Baylink DJ, Johnston CC, Melton LJ, Meunier PJ, Murray TM et al. Fluoride therapy for the vertebral crush fracture syndrome: A status report. Journal of Bone and Mineral Research. 1990;5(SUPPL. 1).
Heaney, R. P. ; Baylink, D. J. ; Johnston, C. C. ; Melton, L. J. ; Meunier, P. J. ; Murray, T. M. ; De Deuxchaisnes, C. N. / Fluoride therapy for the vertebral crush fracture syndrome : A status report. In: Journal of Bone and Mineral Research. 1990 ; Vol. 5, No. SUPPL. 1.
@article{233c8810430f47019374fd26ed9255ba,
title = "Fluoride therapy for the vertebral crush fracture syndrome: A status report",
abstract = "FLUORIDE HAS BEEN PROPOSED as a therapy for the vertebral crush fracture syndrome for many years; such proposals have been based largely on the well-characterized syndrome of fluoride intoxication (fluorosis), which is marked by increased skeletal mass and sometimes exuberant bony overgrowths. For various reasons, including the inability to develop a patentable product, the clinical studies necessary to follow this lead and establish efficacy and safety have proceeded slowly. Nevertheless, much information on fluoride use in the treatment of the vertebral crush fracture syndrome has been amassed, and during the past 9 years fluoride therapy has been approved for this use in Austria, Belgium, France, Germany, Luxembourg, The Netherlands, Norway, and Switzerland. This report represents points of concurrence regarding the efficacy and safety of fluoride therapy and considerations relevant to patient management that were developed among conferees at the International Workshop on Fluoride and Bone, Niagara-on-the-Lake, Ontario, Canada, October 12-15, 1988. Involved in this conference were most of the investigators, worldwide, whose work was the basis for the approval of fluoride use in the European nations just listed. Hence, although the conference concentrated mainly on data not previously available, the conferees were also familiar with the evidence on which the earlier approvals had been made. In evaluating the available studies, especially regarding efficacy, the panel convened to articulate a consensus statement that paid particular attention to the criteria respecting quality of evidence developed by the Canadian Task Force on the Periodic Health Examination, 1988, and the United States Preventive Services Task Force, 1988.",
author = "Heaney, {R. P.} and Baylink, {D. J.} and Johnston, {C. C.} and Melton, {L. J.} and Meunier, {P. J.} and Murray, {T. M.} and {De Deuxchaisnes}, {C. N.}",
year = "1990",
language = "English",
volume = "5",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Fluoride therapy for the vertebral crush fracture syndrome

T2 - A status report

AU - Heaney, R. P.

AU - Baylink, D. J.

AU - Johnston, C. C.

AU - Melton, L. J.

AU - Meunier, P. J.

AU - Murray, T. M.

AU - De Deuxchaisnes, C. N.

PY - 1990

Y1 - 1990

N2 - FLUORIDE HAS BEEN PROPOSED as a therapy for the vertebral crush fracture syndrome for many years; such proposals have been based largely on the well-characterized syndrome of fluoride intoxication (fluorosis), which is marked by increased skeletal mass and sometimes exuberant bony overgrowths. For various reasons, including the inability to develop a patentable product, the clinical studies necessary to follow this lead and establish efficacy and safety have proceeded slowly. Nevertheless, much information on fluoride use in the treatment of the vertebral crush fracture syndrome has been amassed, and during the past 9 years fluoride therapy has been approved for this use in Austria, Belgium, France, Germany, Luxembourg, The Netherlands, Norway, and Switzerland. This report represents points of concurrence regarding the efficacy and safety of fluoride therapy and considerations relevant to patient management that were developed among conferees at the International Workshop on Fluoride and Bone, Niagara-on-the-Lake, Ontario, Canada, October 12-15, 1988. Involved in this conference were most of the investigators, worldwide, whose work was the basis for the approval of fluoride use in the European nations just listed. Hence, although the conference concentrated mainly on data not previously available, the conferees were also familiar with the evidence on which the earlier approvals had been made. In evaluating the available studies, especially regarding efficacy, the panel convened to articulate a consensus statement that paid particular attention to the criteria respecting quality of evidence developed by the Canadian Task Force on the Periodic Health Examination, 1988, and the United States Preventive Services Task Force, 1988.

AB - FLUORIDE HAS BEEN PROPOSED as a therapy for the vertebral crush fracture syndrome for many years; such proposals have been based largely on the well-characterized syndrome of fluoride intoxication (fluorosis), which is marked by increased skeletal mass and sometimes exuberant bony overgrowths. For various reasons, including the inability to develop a patentable product, the clinical studies necessary to follow this lead and establish efficacy and safety have proceeded slowly. Nevertheless, much information on fluoride use in the treatment of the vertebral crush fracture syndrome has been amassed, and during the past 9 years fluoride therapy has been approved for this use in Austria, Belgium, France, Germany, Luxembourg, The Netherlands, Norway, and Switzerland. This report represents points of concurrence regarding the efficacy and safety of fluoride therapy and considerations relevant to patient management that were developed among conferees at the International Workshop on Fluoride and Bone, Niagara-on-the-Lake, Ontario, Canada, October 12-15, 1988. Involved in this conference were most of the investigators, worldwide, whose work was the basis for the approval of fluoride use in the European nations just listed. Hence, although the conference concentrated mainly on data not previously available, the conferees were also familiar with the evidence on which the earlier approvals had been made. In evaluating the available studies, especially regarding efficacy, the panel convened to articulate a consensus statement that paid particular attention to the criteria respecting quality of evidence developed by the Canadian Task Force on the Periodic Health Examination, 1988, and the United States Preventive Services Task Force, 1988.

UR - http://www.scopus.com/inward/record.url?scp=0024994692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024994692&partnerID=8YFLogxK

M3 - Article

VL - 5

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - SUPPL. 1

ER -